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Article Information  ABSTRACT 
Received: 29th Oct 2016  Most of the recently developed new chemical entities are poorly water soluble and they create 
major problems during formulation and development of new dosage form and due to poor 
solubility and poor bioavailability. The drugs belong to BCS class II and class IV has problem 
of solubility, to overcome the solubility problem nanotechnology is most useful technique. In 
this review article the main focus on Nanocrystals and various techniques used for preparation 
of Nanocrystals. Drug nanocrystals consists pure poorly water soluble drugs without any matrix 
material which means that it is carrier free drug delivery. Nanocrystals technologies have been 
introduced as advantageous, universal formulation approaches for the BCS class II and IV 
drugs. Nanocrystals, with greater surface to volume ratio, can effectively increase both the 
dissolution rate and saturation solubility of active ingredients The Nanocrystals is suitable drug 
delivery system for all commonly used routes of administration such as oral, IV, SC, and IM 
and topical application. Nanocrystals can also be incorporated into the tablets, capsules, fast-
melts and lyophilized for sterile product applications. There are no of techniques which are used 
for production including precipitation, milling, high pressure homogenization and combination 
methods such as Nano-Edge, SmartCrystal and Precipitation-lyophilization-homogenization 
(PLH) technology. 
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INTRODUCTION 
Currently one of the main applications of nanotechnology in 
drug delivery is to overcome the problem of poor water 
solubility of hydrophobic drugs. Approximately, 40% of all 
developmental new chemical entities are poorly water soluble 
and therefore, are difficult to formulate [1].The poor solubility 
of drug limits the development of highly potent drug 
formulation. The drugs with low solubility lead to low oral 
bioavailability and erratic absorption which is particularly 
pertinent to drugs within class II of the Biopharmaceutical 
Classification System (BCS). Generally, the rate-limiting step 
for absorption of the drugs in this class is the dissolution 
velocity arising from low solubility. Although the drugs are 
high permeability, the poor solubility results in a low 
concentration gradient between gut and blood vessel 
consequent to a limitation of drug transport and oral absorption. 
Nowadays, there are a large percentage of drug compounds in 
drug development represents as poor aqueous solubility. 
Conventional formulations of poorly-water soluble drugs are 
frequently facing the problems such as poor and highly variable 
bioavailability. The dosage form is often times affected by the 
fed–fasted state of the patient and its onset of action is slower 
than anticipated. All of these issues lead to sub-optimal dosing 
and poor performance. Therefore, one of the most challenging 
tasks in drug development is to improve the drug solubility in 
order to enhance the bioavailability of these drugs. The 
approaches to increase the solubility and the available surface 
area for dissolution are classified as physical and chemical 
modifications. For the physical modification, the techniques 
include decreasing particle size (micronization, nanonization), 
formation of polymorphs/pseudo polymorphs (including 
solvates), complexation/ solubilization (by means of using 
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surfactants or cyclodextrins, conjugation to dendrimers, and an 
addition of co-solvents) and preparation of drug dispersions in 
carriers (eutectic mixtures, non-molecular solid dispersions, 
solid solutions). For the chemical modification, the used 
technique is the synthesis of soluble prodrugs and salts. The 
micronization of drugs is applied to increase their surface area. 
Increasing the surface area will proportionally increase the rate 
of dissolution and the rate of diffusion (absorption). 
Micronization cannot improve the saturation solubility of a 
drug substance. Consequently, the next step was taken to move 
from micronisation to nanonisation that means producing drug 
nanocrystals. [2] Drug nanocrystals are crystals with a size in the 
nanometer range, which means they are nanoparticles with a 
crystalline character. There are discussions about the definition 
of a nanoparticle, which means the size of a particle to be 
classified as a nanoparticle, depending on the discipline e.g., in 
colloid chemistry particles are only considered as nanoparticles 
when they are in size below 100 nm or even below 20 nm. 
Based on the size unit, in the pharmaceutical area nanoparticles 
should be defined as having a size between a few nanometers 
and 1000 nm (=1 μm); micro particles therefore possess a size 
of 1–1000 μm [3, 4]. A further characteristic is that drug 
nanocrystals are composed of 100% drug; there is no carrier 
material as in polymeric nanoparticles. Dispersion of drug 
nanocrystals in liquid media leads to so called 
“Nanosuspensions” (in contrast to “micro suspensions” or 
“macro suspensions”). In general the dispersed particles need 
to be stabilized, such as by surfactants or polymeric stabilizers. 
Dispersion media can be water, aqueous solutions or 
nonaqueous media (eg, liquid polyethylene glycol [PEG], oils). 
Depending on the production technology, processing of drug 
microcrystals to drug nanoparticles can lead to an either 
crystalline or to an amorphous product, especially when 
applying precipitation. In the strictest sense, such an 
amorphous drug nanoparticle should not be called nanocrystals. 
However, often one refers to “nanocrystals in the amorphous 
state. [5, 6] 
 
ADVANTAGES OF NANOCRYSTALS 
 It can be given by any route of administration. 
 Enhanced solubility and bioavailability of drug. 
 Reduced tissue irritation in case of 
subcutaneous/intramuscular administration. 
 Rapid dissolution & tissue targeting can be achieved by IV 
route of administration. 
 Oral administration of Nano suspension provide rapid 
onset, reduced fed/fasted ratio& improved bioavailability. 
 The absorption form absorption window can be increased, 
due to reduction in the particle size. 
 It can be incorporated in tablets, pellets, hydrogel & 
suppositories are suitable for various routes of 
administration. 
 Increasing the amorphous fraction in the particles leading 
to a potential change in the crystalline structure & higher 
solubility. 
 Possibility of surface-modification of Nanosuspension for 
site specific delivery. 
 Higher drug loading can be achieved. 
 Long term physical and chemical  stability (due to absence 
of Ostwald ripening)[7,8] 
 
DISADVANTAGES OF NANOCRYSTALS 
 Physical stability, sedimentation & compaction can cause 
problems. 
 It is bulky sufficient care must be taken during handling & 
transport. 
 Uniform & accurate dose cannot be achieved[7,8] 
 
PROPERTIES OF NANOCRYSTALS 
 Increase of dissolution velocity by surface area 
enlargement 
The size reduction leads to an increased surface area and thus 
according to the Noyes-Whitney equation to an increased 
dissolution velocity. Therefore micronization is a suitable way 
to successfully enhance the bioavailability of drugs where the 
dissolution velocity is the rate limiting step. By moving from 
micronization further down to nanonization, the particle surface 
is further increased and thus the dissolution velocity increases 
too. In most cases, a low dissolution velocity is correlated with 
low saturation solubility. Noyes and Whitney Equation: 
𝑑𝑐
𝑑𝑡
=  
𝐷𝐴
ℎ
(𝐶𝑠 − 𝐶𝑥) 
Where, dc/dt is dissolution velocity, D is diffusion coefficient, 
A is surface of the drug particle, h is thickness of diffusional 
layer, Cs is saturation solubility of the drug and Cx is 
concentration in surrounding liquid at time 
 
 Increase in saturation solubility 
The saturation solubility Cs is a constant depending on the 
compound, the dissolution medium and the temperature. This is 
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valid for powders of daily life with a size in the micrometer 
range or above. However, below a critical size of 1–2 μm, the 
saturation solubility is also a function of the particle size. It 
increases with decreasing particle size below 1000 nm. 
Therefore, drug Nanocrystals possess increased saturation 
solubility. This has two advantages: 
i. According to Noyes and Whitney equation, the dissolution 
velocity is further enhanced because dc/dt is proportional 
to the concentration gradient (Cs−Cx)/h (Cs- saturation 
solubility, Ct - bulk concentration, h- diffusional distance). 
ii. Due to the increased saturation solubility the concentration 
gradient between gut lumen and blood is increased, 
consequently the absorption by passive diffusion. 
 
 The saturation solubility of solid particles depends on 
their particle radius and their lattice structure according to 
the Ostwald-Freunlich equation and the Kelvin equation 
In
S
So
= 
2
rRT
= 
2M
rRT
 
Where, S is the drug solubility at temperature T,                         
S0 the solubility if r = ∞, M the molecular weight of the 
compound, υ the molar volume, γ the interfacial surface 
tension, and ρ the density of the compound. From the Ostwald-
Freunlich equation, it can be concluded that a drug shows 
higher solubility if the particle radius is decreased. This effect 
is not substantial for larger particles but will be more 
pronounced for particles below 1 to 2 μm, especially well under 
200 nm. Another important factor influencing the solubility is 
the crystalline structure of the drug. The higher the solid 
density and the melting point are, the lower the solubility. In 
contrast, a polymorph form with a lower packaging shows a 
higher molar volume and lower solid density. [9, 10]  The Kelvin 
equation can also be used to describe the correlation of 
increased saturation solubility by decreased particle size. The 
Kelvin equation describes the vapor pressure as a function of 
the curvature of liquid droplets in a gas phase. The vapor 
pressure increases with increasing curvature (decreasing 
particle size). [9] 
 
TECHNIQUES FOR MANUFACTURING OF 
NANOCRYSTALS  
1.  Bottom up technology                 
1.1 Anti-solvent precipitation                 
1.2 Supercritical fluids                 
1.3 Spray-drying 
 2.  Top down Technology              
2.1 Media milling                      
        2.1.1. Bead milling                     
2.1.2. Dry co-grind             
2.2 High pressure homogenizations                    
2.2.1. Homogenization in Aqueous media (Disso cubes)                 
2.2.2. Homogenization in Non Aqueous Media (Nanopure)                   
2.2.3 Nanojet technology               
2.3 Emulsion solvent diffusion method  
3. Combination technology                 
3.1 NANOEDGE® Technology                
3.2 SmartCrystal® Technology 
 4. Other methods             
 4.1. Solvent evaporation                
4.2. Sonocrystallization              
4.3. Melt emulsification             
4.4. Bottom-Up NanoCrySP Technology    
 
1. Bottom up technology  
Principal of this technology is based on precipitation by 
dissolving the drug in a solvent and adding the solvent to a 
non-solvent that cause precipitation of the fine drug particle. 
1.1 Precipitation technology (Antisolvent method): 
In this technique the drug is dissolved in an organic solvent in 
which it is soluble and this solution is mixed with a miscible 
Antisolvent for precipitation in presence of stabilizer. In the 
water-solvent mixture the solubility is low and the drug 
precipitate out. Precipitation has also been combined with high 
shear processing. This is accomplished by a combination of 
rapid precipitation and high-pressure homogenization. The 
Baxter healthcare company introduced their patented 
technology US 6,884,436 known as NANOEDGE. This 
technology based on precipitation of friable materials for 
fragmentation under conditions of high shear and/or thermal 
energy. Sudden super saturation of the mixed solution occurs 
by rapid addition of drug solution to Antisolvent and 
generation of fine crystalline or amorphous solids. Precipitation 
of an amorphous material may be favored at high super 
saturation when the solubility of the amorphous state is 
exceeded. Precipitation method is the preparation of amorphous 
drug nanoparticles, for example, as carotene nanoparticles in 
the food industry. e.g., Lucarotin® or Lucantin® (BASF). A 
solution of the carotenoid, together with a surfactant in a 
digestible oil, are mixed with an appropriate solvent at a 
specific temperature. To obtain the solution a protective colloid 
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is added. This leads to an O/W two phase system. The 
carotenoid stabilized by the colloid localizes in the oily phase. 
After lyophilization X-ray analyzes shows that approximately 
90% of the carotenoid is in an amorphous state.[10] 
 
1.2 Supercritical fluid methods 
Nanoparticles are produced by various methods like rapid 
expansion of supercritical solution (RESS) process, 
supercritical Antisolvent process, and precipitation with 
compressed Antisolvent (PCA) process. In RESS technique, 
drug solution is expanded through a nozzle into supercritical 
fluid, resulting in precipitation of the drug as fine particles by 
loss of solvent power of the supercritical fluid. Young et al. 
prepared cyclosporine nanoparticles having diameter of 400 to 
700 nm by using this technique. In the PCA method, the drug 
solution is atomized into the CO2 compressed chamber. As the 
removal of solvent occurs, the solution gets supersaturated and 
finally precipitation occurs. In supercritical Antisolvent 
process, drug solution is injected into the supercritical fluid and 
the solvent gets extracted as well as the drug solution becomes 
supersaturated. The basic disadvantages of this methods are use 
of hazardous solvents and use of high proportions of 
surfactants and stabilizers as compared with other techniques.   
 
1.3 Spray drying 
This method is usually used for drying of solutions and 
suspensions. In a conical or cylindrical cyclone, solution 
droplets are sprayed from top to bottom, dried in the same 
direction by hot air and spherical particles are obtained. 
Spraying is made with an atomizer which rapidly rotates and 
provides scattering of the solution due to centrifugal effect. The 
solution, at a certain flow rate, is sent to the inner tube with a 
peristaltic pump, nitrogen or air at a constant pressure is sent to 
the outer tube. Spraying is provided by a nozzle. Droplets of 
solution become very small due to spraying; therefore, surface 
area of the drying matter increases leading to fast drying. 
Concentration, viscosity, temperature and spray rate of the 
solution can be adjusted and particle size, fluidity and drying 
speed can be optimized. The dissolution rate and bioavailability 
of several drugs, including hydrocortisone, COX-2 Inhibitor 
(BMS-347070) were improved utilizing this method.[11] 
 
2. Top down technology 
The „Top down Technologies‟ are the disintegration methods 
and are preferred over the precipitation methods. 
2.1 Media milling (Nanocrystals or Nano systems) 
2.1.1. Bead milling: The method is first developed by 
liversidge et. al. In this method the Nanosuspensions are 
produced using high‐shear media mills or pearl mills. The 
media mill consists of a milling chamber, a milling shaft and a 
recirculation chamber. Shear forces of impact, generated by the 
movement of the milling media, lead to particle size reduction 
the milling medium is made up of glass, zirconium oxide or 
highly cross‐linked polystyrene resin. The milling chamber is 
fed with the milling media, water, drug and stabilizer and then 
milling media or pearls are then rotated at a very high shear 
rate. The milling process is performed under controlled 
temperatures. The Nanosuspension or nanoparticles are form as 
result of high energy and shear forces generated due to the 
impaction of the milling media with the drug which provide the 
energy input to break the micro particulate drug into 
Nano‐sized particles. The media milling procedure can 
successfully process micronized and non‐micronized drug 
crystals.. To reduce the amount of impurities caused by erosion 
of the milling media, the milling beads are coated. There are 
two basic milling principles. Either the milling medium is 
moved by an agitator, or the complete container is moved in a 
complex movement leading consequently to a movement of the 
milling media. The milling time depends on many factors such 
as the surfactant content, hardness of the drug, viscosity, 
temperature, energy input, size of the milling media. The 
milling time can last from about 30 minutes to hours or several 
days. [12] 
 
2.1.2. Co-grinding 
Stable Nanoosuspensions are formulated using dry grinding of 
poorly soluble drugs with soluble polymers and copolymers 
after dispersing in a liquid media.  It is the colloidal particles 
formation of many poorly water soluble drugs; griseofulvin, 
glibenclamide and nifedipine obtained by grinding with 
polyvinylpyrrolidone (PVP) and sodiumdodecylsulfate (SDS). 
Various soluble polymers and co-polymers such as PVP, 
polyethylene glycol (PEG), hydroxypropyl methylcellulose 
(HPMC) and cyclodextrins derivatives have been used. By 
using this method the physicochemical properties and 
dissolution of poorly water soluble drugs were improved 
because of an improvement in the surface polarity and 
transformation from a crystalline to an amorphous drug. Dry co 
grinding can be carried out easily and economically and can be 
conducted without need of organic solvents. 
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2.2 High Pressure Homogenization 
When producing nanocrystals using homogenization methods, 
there are three important technologies namely: Microfluidizer 
technology (Nanojet technology), Piston gap homogenization 
in aqueous media (Dissocubes® technology) and in water 
mixtures or in nonaqueous media (Nanopure® technology)[2] 
 
2.2.1. Microfluidizer Technology (Nanojet technology) 
This technology called opposite stream or Nanojet technology. 
This method consist of Microfluidizer which uses a chamber 
where a stream of suspension is divided into two or more parts, 
which colloid with each other at high pressure. This leads to 
particle collision, shear forces and also cavitation forces.  
 
The high shear force produced during the process due particle 
collision and high pressure results in particle size reduction. 
Equipment using this principle includes the M110L and M110S 
micro fluidizers. Dearn prepared Nanoosuspensions of 
atovaquone using the micro fluidization process. The major 
disadvantage of this technique is the high number of passes 
through the micro fluidizer and that the product obtained 
contains a relatively larger fraction of microparticles. 
 
2.2.2. Piston gap homogenization in aqueous media 
(Dissocubes) 
This technology was developed by R.H.Muller in 1999 and 
first patent was taken by DDS Gmbh and afterward the patent 
was transferred to Skype pharmaceuticals. Commonly used 
homogenizer are the APVMicron Lab 40 (APV Deutschland 
Gmbh, Lubeck, Germany)and  piston-gap homogenizers. In 
this method, the suspension containing a drug and surfactant is 
forced under pressure through a Nanosized aperture valve of a 
high pressure homogenizer. In this method the particle size 
reduction depend on cavitation principle.  
 
The dispersion present in 3cm diameter cylinder is suddenly 
passed through a very narrow gap of 25µm. According to 
Bernoulli‟s law the flow volume of liquid in a closed system 
per cross section is constant. It leads to increase in dynamic 
pressure and decrease of static pressure below the boiling point 
of water at diameter from 3cm to 25µm.Then water starts 
boiling at room temperature and forms gas bubbles, which 
implode when the suspension leaves the gap (called cavitation) 
and normal air pressure is reached. The particles cavitation 
forces are sufficiently high to convert the drug micro particles 
into nanoparticles. In this the final particle size of drug 
nanocrystals is based on power density of homogenizer, 
number of homogenization cycles, temperature and 
homogenization pressure. 
 
2.2.3 Homogenization in Non Aqueous Media (Nanopure) 
In this technology suspension is homogenized in water-free 
media or water mixtures. In the Dissocubes technology the 
cavitation is the principle determining factor of the process oils 
and oily fatty acids have very low vapour pressure and a high 
boiling point as compare to water. Hence, the drop of static 
pressure will not be sufficient enough to initiate cavitation. 
Patents covering disintegration of polymeric material by high- 
pressure homogenization mention that higher temperatures of 
about 80°C promoted disintegration, which cannot be used for 
thermo labile compounds. In Nanopure technology, the drug 
suspensions in the non aqueous media were homogenized at 
0°C or even below the freezing point and hence are called 
"deep-freeze" homogenization. The results obtained were 
comparable to Dissocubes and hence can be used effectively 
for thermo labile substances at milder conditions. [2] 
 
2.3. Emulsion solvent diffusion method 
The use of emulsions as templates is applicable for those drugs 
that are soluble in either volatile organic solvent or partially 
water‐miscible solvent. Such solvents can be used as the 
dispersed phase of the emulsion. An organic solvent or mixture 
of solvents loaded with the drug is dispersed in the aqueous 
phase containing suitable surfactants with stirring to form an 
emulsion. The obtained emulsion was further homogenized by 
high pressure homogenization. After homogenization cycles 
the emulsion was diluted with water, homogenized by 
homogenizer to diffuse the organic solvent and convert the 
droplets into solid particles.  
 
Since one particle is formed in each emulsion droplet, it is 
possible to control the particle size of the Nanosuspension by 
controlling the size of the emulsion. Optimizing the surfactant 
composition increases the intake of organic phase and 
ultimately the drug loading in the emulsion. Originally 
methanol, ethanol, ethyl acetate, chloroform are used as 
organic solvents. However, environmental hazards and human 
safety concerns about residual solvents have limited their use in 
routine manufacturing processes. Nanosuspension of ibuprofen, 
diclofenac, and acyclovir were prepared by this method. 
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3. Patented Technologies  
3.1 NANOEDGE™ 
The basic principles of NANOEDGE are the same as that of 
precipitation and homogenization. A combination of these 
techniques results in smaller particle size and better stability in 
a shorter time. The major drawback of the precipitation 
technique, such as crystal growth and long term stability, can 
be resolved using the NANOEDGE technology. In this 
technique, the precipitated suspension is further homogenized; 
leading to reduction in particle size and avoiding crystal 
growth. Precipitation is performed in water using water-
miscible solvents such as methanol, ethanol and isopropanol. It 
is desirable to remove those solvents completely, although they 
can be tolerated to a certain extent in the formulation. For an 
effective production of Nanosuspensions using the 
NANOEDGE technology, an evaporation step can be included 
to provide a solvent-free modified starting material followed by 
high-pressure homogenization. [13] 
 
3.2 SmartCrystal® technology  
This technology was first developed by PharmaSol GmbH and 
was later acquired by Abbott.  It is a tool-box of different 
combination processes in which process variations can be 
chosen depending upon the physical characteristics of the drug 
(such as hardness). The process H42 involves a combination of 
spray-drying and HPH. Within few homogenization cycles the 
nanocrystals is prepared. Process H69 (Precipitation and HPH) 
and H96 (lyophilization and HPH) yield nanocrystals of 
amphotericin B within a size range of about 50 nm. S. 
Kobierski et al. (2008) produced nanocrystals in a two-step 
process i.e. pre- milling followed by high pressure 
homogenization (HPH). Nanosuspensions of cosmetic active 
hesperidin were produced by ball milling process and with 
combination process. Prepared nanosuspensions were kept for 
storage. Nanosuspension prepared using SmartCrystal® 
technology was found to be of a smaller size indicating better 
physical stability[13]  
 
4. Other technologies  
4.1 Solvent Evaporation  
In this method, the solutions of polymer are prepared in volatile 
solvents and emulsions. But from last few years 
dichloromethane and chloroform were used which was now 
replaced by ethyl acetate which has a better profile of 
toxicology. The emulsion is converted into a nanoparticle 
suspension on evaporation of the solvent for the polymer, 
which is allowed to diffuse through the continuous phase of the 
emulsion. In the conventional methods, two main strategies are 
being used for the formation of emulsions, the preparation of 
single emulsions, e.g., oil-in-water (o/w) or double-emulsions, 
e.g., (water-in-oil)-in-water, (w/o)/w. These methods require 
high-speed homogenization or ultrasonication, followed by 
evaporation of the solvent, either by continuous magnetic 
stirring at room temperature or under reduced pressure. By 
ultracentrifugation the solidified nanoparticles are collected 
which was washed with distilled water to remove the additives 
like surfactants, and then it was lyophilized. The particle size 
was influenced by the concentration of polymer, stabilizer and 
the speed of homogenizer. 
 
4.2 Sonocrystallization  
The novel approach for particle size reduction on the basis of 
crystallization by using ultrasound is Sonocrystallization. 
Sonocrystallization utilizes ultrasound power characterized by 
a frequency range of 20-100 kHz for inducing crystallization. It 
not only enhances the nucleation rate but also an effective 
means of size reduction & controlling size distribution of the 
active pharmaceutical ingredient (API). Most applications used 
ultrasound in the range 20 kHz -5 MHz Sonocrystallization 
technique or technology has also been studied to modify the 
undesirables of NSAID‟S i.e. poor solubility and dissolution 
rate and consequently the poor bioavailability.  
 
4.3. Melt emulsification method  
Solid lipid nanoparticles are mainly prepared by melt 
emulsification method. Kipp and coworkers firstly prepare 
Nanosuspensions of ibuprofen by using melt emulsification 
method. It is a four-step procedure. Drug is first added to 
aqueous solution having stabilizer. The solution is heated at 
temperature higher than the melting point of the drug and then 
homogenized by high-speed homogenizer for the formation of 
emulsion. The temperature is maintained above the melting 
point of the drug during overall process. Finally, the emulsion 
is cooled to precipitate the particles. The particle size of 
Nanosuspension mainly depends on parameters like drug 
concentration, concentration and type of stabilizers used, 
cooling temperature, and homogenization process. 
4.4. Bottom-Up NanoCrySP Technology 
G. Shete, Y. Pawar et al, National Institute of Pharmaceutical 
Education and Research (NIPER) introduced a newer  method 
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to  generate Nano crystalline solid dispersion (NSD) of 
hesperetin using NanoCrySP technology: a novel bottom-up 
process based on spray drying to generate solid particles 
containing drug nanocrystals dispersed in the matrix of small 
molecule excipients (WO2013132457 A2). The purpose of 
their study to improved oral bioavailability and 
pharmacodynamics activity of hesperetin nanocrystals 
generated using a novel bottom-up NanoCrySP Technology.  
Hesperetin and mannitol were used in 1:1 ratio and NSD was 
generated using spray drying. The process of NSD formation is 
based on classical nucleation theory wherein mannitol 
contributed to crystallization of hesperetin by acting as 
plasticizer, crystallization inducer and by providing 
heterogeneous nucleation sites. Hesperetin was found to exist 
as nanocrystals dispersed in the matrix of mannitol with 
average crystallite size of 137 nm in the NSD. [14]   
 
NANOCRYSTAL STABILIZERS 
The number of impressive advantages of nanocrystals, small 
size of nanocrystals can often lead to stability concerns. The 
large surface area of nanocrystals results in sufficiently high 
free energy or surface charge that might cause attraction or 
agglomeration. [15] Small sized Nanocrystals sometimes raise 
the solubility of drug beyond the saturation point which 
promotes recrystallization into larger particles; also known as 
Ostwald ripening. These processes ultimately lead to 
irreversible loss of formulation integrity. [16]  There are number 
of stabilizers are used for stabilization of Nanocrystals 
 
a. Poloxamer 
Poloxamer are amphiphilic block copolymers formed with a 
combination of ethylene oxide (E; hydrophilic) and propylene 
oxide (P; hydrophobic) units arranged in an E–P–E 
arrangement. Poloxamers are available in various grades 
developed using different lengths of polymer blocks. They not 
only serve as ideal stabilizers but also presume the capacity to 
chemosensitize the multiple drug resistance (MDR) cells. 
Poloxamers are certified as generally recognized as safe 
(GRAS) excipient and considerably cause negligible hemolytic 
reaction hence they are popular for delivery of drugs through 
intravenous route. [19]They have been widely used for the 
stabilization of nanocrystals. Poloxamer 188 appended 
omeprazole nanocrystals showed enhanced stability due to 
shielding of the compound and on comparison with omeprazole 
solution, Researchers have also utilized Poloxamer 407 for the 
development of several nanocrystals formulations. Deng et 
al.attempted to improve the therapeutic profile of paclitaxel by 
stabilizing its nanocrystals using poloxamer 407, but failed, and 
ended up with thermosensitive miceller structure. However, 
renanonization with incubation sonication led to formation of 
nanocrystals with prolonged stability.[17,18] 
 
b. Polyvinyl Pyrrolidone (PVP) 
PVP or povidone is prepared by reaction of acetylene and 
pyrrolidone to form vinyl pyrrolidone followed by 
polymerization to convert into PVP. It is available in different 
viscosity grades having a versatile range of application from 
being a binder in tablets and capsules, film formers in 
ophthalmic solution, taste masking agent, toxicity reducer and 
the most important as a stabilizer in suspensions[19].PVP K30 
has been applied as a stabilizer for formation of celecoxib 
Nanocrystals Remarkably, it was seen that combination of 
stabilizers did not affect the crystallinity of drug when 
characterized by DSC; however a reduction of melting point 
was seen due to generation of new crystalline state.[21] PVP 
K17 and K12 demonstrated the versatile applications of PVP 
when they were tried for the preparation of probucol 
nanocrystals. The study established the fact that PVP or SDS 
alone was incapable to prevent agglomeration whereas 
combination of both resulted in a stable formulation.[20] 
 
c. Polyvinyl alcohol (PVA) 
Properties of the water soluble PVA are dependent upon the 
degree of polymerization and extent of hydrolysis. Partially 
hydrolysed PVA is generally used in pharmaceutical 
industry.[22] It has been used in formulating stable nitrendipine 
(a class II calcium channel blocker) nanocrystals through 
precipitation ultra-sonication method with resultant improved 
dissolution characteristics which in turn increased its oral 
bioavailability.[23] 
 
d. Amino acid derived co-polymers 
Albumin, a single polypeptide chain of 585 amino acids, is 
generally used as stabilizing agent for parenteral formulations 
containing protein and enzyme. Leucine (C6H13NO2) has 
gained usage as a lubricant and an antiadherent in the 
development of aqueous nanocrystals formulation. Lee et al., 
tried combination of various co-polymers derived from amino 
acids to stabilize nanocrystals consisting of naproxen. 
Nanoformulations were developed using two polymeric 
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combinations made of lysine, leucine, and albumin. Out of 
these two combinations its use is often associated with 
anaphylactic hypersensitivity reactions, hyperlipidemia, 
abnormal lipoprotein patterns, aggregation of erythrocytes and 
peripheral neuropathy.[24,26] 
 
e. Lecithin 
Lecithin is mixture of phosphatides with triglycerides, fatty 
acids and carbohydrates. Due to their lipid content, they form 
an integral part of many nutritional formulations. When used in 
pharmaceutical industry, they excel as stabilizer or emulsifiers. 
Their physical forms may vary from being powders or semi 
liquids based on their free fatty acid content and they also pose 
good absorption enhancing property. Being derived from 
natural sources (egg and soya) they find wide acceptance as 
stabilizer for a variety of drugs. Lecithin was used in 
combination with Poloxamer 188 and HPMC to stabilize 
amoitone B, an anticancer agent. Yang et al., have employed 
dipalmitoyl phosphatidylcholine (a lecithin; endogenous 
component of human lung surfactant) to formulate nebulized 
itraconazole nanocrystals with improved bioavailability. The 
presence of dipalmitoyl phosphatidylcholine ultimately 
improved the overall in-vivo presence of itraconazole due to its 
permeation enhancement property. 
 
f. Brij 
It is used as emulsifying, wetting and a permeation enhancing 
agent, Brij-78 is a non-ionic surfactant containing 
Polyoxyethylene alkyl ethers and also termed as Cremophor. 
Nanocrystals obtained by processing oridonin were stabilized 
using Brij-78 by Gao et al. However, its use is often associated 
with anaphylactic hypersensitivity reactions, hyperlipidemia, 
abnormal lipoprotein patterns, aggregation of erythrocytes and 
peripheral neuropathy.[26] 
 
g. Polysorbate 80 
A Polyoxyethylene sorbitan fatty acid ester derivative has 
established itself as an important pharmaceutical excipient. 
They are classified according to type of fatty acid moiety which 
influences their functions. It has been utilized on the large scale 
as surface active agent however its propensity towards causing 
hypersensitivity, birth weight reduction in infants and other 
side effects when used in high concentration can sometimes be 
a deterrent. Therefore researchers often tend to utilize 
Polysorbate 80 at low levels as a complimentary stabilizer. It 
has been tried in combination with poloxomer 188, PVA, PVP 
and SDS for developing fenofibrate nanocrystals.[27] 
 
h. Sodium lauryl sulphate 
A sulphuric acid monododecyl ester sodium salt, is an anionic 
surfactant used widely as a wetting agent however it exerts 
moderate toxic effects including irritation of the eyes, skin and 
stomach. It has been used to developed nanocrystals of 
herpetrione, an antiviral agent extracted from herpetospermum 
caudigerum, via high pressure homogenization technique 
followed by freeze drying. 
 
i. HPMC 
It is a widely used GRAS listed pharmaceutical excipient that 
has found special use in formulation of nanocrystals and is 
believed to cover the surface of crystal efficiently providing 
sufficient stability. In comparison to other stabilizers, its 
relatively high melting point makes it a robust option for 
production methods which involve high processing 
temperature. Recently, Ali et al., utilized HPMC as a 
stabilizing agent in media milling process of hydrocortisone 
nanocrystals intended for ophthalmic delivery. HPMC played a 
key role in stabilizing the nanocrystals by completely covering 
the surface of dried particle and gave it a low zeta potential. 
Figueroa et al., prepared HPMC based fenofibrate, naproxen, 
and griseofulvin (BCS class-II drug) nanocrystals. Inferences 
showed that HPMC was able to maintain the crystallinity of the 
bioactive. Hecq et al., used HPMC for producing nanocrystals 
of nimodipine.It using high pressure homogenization. The 
technology was utilized with the aim of formulating 
nanocrystals to improve the dissolution rate of nifedipine. The 
use of low viscosity grade HPMC provided adequate stabilizing 
effect compared to other surface active agents like SDS, 
poloxamer and polysorbate.[28,29] 
 
j. Sodium cholic acid 
Bile acid derived white crystalline powder is employed to 
stabilize many nanocrystals based formulations. In combination 
with poloxomer 188, it has been used to stabilize nimodipine.It 
nanocrystals. Nimodipine.It is regarded as a drug of choice for 
reducing both morbidity and mortality in subarachnoid 
haemorrhage related vasospasm. The clinically available 
injectable form of the drug is administered with alcohol and 
PEG 4000 which is associated with numerous allergic 
reactions. The sodium cholic acid stabilized nanocrystals thus 
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offered a novel approach in which the excipients did not 
adversely affect the risk–benefit ratio and open an option for 
intravenous administration of nimodipine.It has also been used 
for stabilization of cyclosporine nanocrystals.[30] 
 
APPLICATION OF NANOCRYSTALS: 
1. Oral drug delivery 
Oral route has been the most preferred route and is considered 
as the safest and suitable route for drug delivery. [31,32]For orally 
administered drugs, dissolution is considered as a rate 
determining step for absorption. Nanocrystals provide a greater 
surface area for dissolution and thus raising the saturation 
solubility which ultimately increases the dissolution rate 
thereby enhancing drug absorption. Muller et al., have refined 
oral delivery of thermo stable drugs utilizing melted PEG 
(melting point at 60 °C) which allows fixing of nanocrystals in 
a solid PEG matrix. Nanocrystals dispersed in melted PEG 
were milled to powder and directly compressed into the tablet 
or filled in capsules shell. Thus, this novel drug delivery system 
offers a way to incorporate poorly soluble drugs directly into 
tablet, capsule or hot melts solid matrix to improve oral 
bioavailability.[33] 
 
2. Intravenous drug delivery 
Administering a drug via intravenous route provides numerous 
benefits such as immediate action, reduced dosing and 100% 
bioavailability. The use of intravenous route is limited because 
harmful solvent and excipients, which are used during 
formulation development, are also co-administered with the 
drug and they can cause serious side effects other than the drug 
itself. Nanocrystals could be considered as the ideal candidates 
for intravenous delivery because their developmental processes 
do not employ excess use of such harmful excipients.[33] 
 
3. Pulmonary drug delivery 
Lungs are highly perfused organs with a fully expanded surface 
area roughly equivalent to three football fields. Due to lack of 
hepatic portal drainage, molecular dispersion of drug is rapidly 
transported into the systemic circulation with high efficiency.  
Recently, it has been demonstrated that pulmonary nanocrystals 
have the ability to rival pharmacokinetics offered by 
intravenous administration of baicalin. Pulmonary route thus 
comes across as a viable option for delivery of therapeutics. 
Due to constant exposure to external environment, it is highly 
susceptible to disease causing agents; allergens and pathogens 
easily invade through the respiratory tract. Conventional 
modalities of deep lung drug deposition have been modified by 
tailoring size of nanocrystals. A nebulizer is generally required 
to administer powdered nanocrystals. Nebulizer can 
incorporate nanocrystals into small inhalable droplets (1–5 
μm).[33,34] 
 
4. Ocular drug delivery 
Ophthalmic drug delivery is a challenging task owing to critical 
pharmacokinetic environment and physiological barriers of the 
eye that hinder the delivery of drugs. Most of the drugs for 
ocular therapy are delivered through a topical formulation in 
the form of solution or suspension. Conventional formulations 
are subjected to rapid clearance from application site due to 
rapid eye movements (blinking) and lacrimation, which results 
in low ocular availability. Short retention time of medication 
induces a need of repeated dosing relatable with loss in patient 
compliance and dose dependent side effects. To alleviate these 
rapid filings, several approaches like ocular inserts and 
ophthalmic gels have been tried, which themselves are 
associated with fair share of inadequacies, viz. poor therapeutic 
outcome, blurred vision and local irritation. Ophthalmic drug 
delivery was believed to be benefited largely by a colloidal 
drug delivery system. Piloplex, the first novel colloidal drug 
delivery system developed, contains pilocarpine which is 
ionically bounded to poly (methyl) methacrylate-co acrylic acid 
nanoparticles.  
 
Subsequently, nanocrystals technology played an advanced role 
in ophthalmic drug delivery tackling dispersibility issues of 
poorly soluble drugs such as budesonide, dexamethasone, 
hydrocortisone prednisolone and fluorometholone. Ali et al., 
used combination technology based upon microfluidic 
nanoprecipitation and wet milling to create nanocrystals of 
hydrocortisone and ocular bioavailability was evaluated in 
albino rabbits. Results demonstrated an extended duration of 
action and significantly improved AUC of developed 
nanocrystals in comparison to free drug. A markedly advanced 
ophthalmic delivery system for forskolin (intra ocular pressure 
lowering agent) was developed by incorporating its 
nanocrystals into an in-situ gelling system comprised of 
poloxamer and polycarbophil. Pharmacodynamics studies 
revealed that nanocrystals/hydrogel system efficiently lowered 
the intraocular pressure up to 12 hrs in comparison to 
conventional suspension. 
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5. Bioavailability Enhancement 
Some of newly developed molecules having the problem of 
poor water solubility so resulting poor permeability. 
Nanosuspensions resolve the problem of poor bioavailability 
by solving the twin problems of poor solubility and poor 
permeability across the membrane. As compared to 
conventional naproxen the oral administration of naproxen 
nanoparticles lead to an area under the curve (AUC) (0-24 h) of 
97.5 mg-h/l which is just 44.7 mg-h/l for naproxen suspensions 
and 32.7 mg-h/l for anaprox tablets. The Oral administration of 
the gonadotropin inhibitor in conventional dispersion 
(Danocrine) only shows 5.2% absolute bioavailability but in 
the form of Nanosuspension Danazol it‟s about 82.3%. Kayser 
et al. developed the Nanosuspension Amphotericin B showed a 
significant improvement in its oral absorption in comparison 
with the conventional commercial formulation.[13] 
 
6. Targeted Drug Delivery 
Nanosuspensions can be used for targeted delivery as their 
surface properties and in-vivo behavior can easily be altered by 
changing either the stabilizer or the milieu. The engineering of 
stealth Nanoosuspensions (analogous to stealth liposomes) by 
using various surface coatings for active or passive targeting of 
the desired site is the future of targeted drug delivery systems. 
Kayser et al formulated a nanosuspension of Aphidicolin to 
improve drug targeting against leishmania infected 
macrophages. He stated that nanosuspension formulation had 
an enhanced activity with an EC (50) of 0.003 mcg/ml which is 
about 0.16mcg/ml in the conventional form. Scholer et al. 
showed an improved drug targeting to the brain in the treatment 
of toxoplasmic encephalitis in a new murine model infected 
with Toxoplasma gondii using a nanosuspension formulation of 
Atovaquone.[13] 
 
MARKETED FORMULATION OF NANOCRYSTALS 
1. Rapamune 
It was the first US FDA approved oral nanocrystals launched in 
the year 2000 by Wyeth Pharmaceuticals (Madison, NJ). It 
consists of Sirolimus nanocrystals incorporated in an excipient 
mixture suited for direct compression into palatable tablets. 
The oral bioavailability of the nanocrystals tablets was 21% 
higher compared to Sirolimus solution. Previously Rapamune 
available only as an oral solution which requires refrigeration 
storage and mixed with water and orange juice prior to 
administration[35] 
2. Emend 
It was introduced market in 2001 by Merck (Winehouse 
Station, NJ), it consists of Aprepitant, which is generally used 
for treatment of emesis. Aprepitant is a selective, high-affinity 
antagonist of human substance P/neurokinin 1 (NK 1) 
receptors. Aprepitant has little or no affinity for serotonin (5-
HT 3), dopamine, and corticosteroid receptors, the targets of 
existing therapies for chemotherapy-induced nausea and 
vomiting (CINV). Aprepitant has been shown in animal models 
to inhibit emesis induced by cytotoxic chemotherapeutic 
agents, such as cisplatin, via central actions. Emend is capsule 
containing 80 or 125 mg of Aprepitant formulated as 
Nanocrystals drug particles.[36] 
 
3. Tricor 
It was introduced in market by Abbott Laboratories and the 
active ingredient is fenofibrate, being available in 48 mg and 
145 mg tablets). Tricor is indicated as adjunctive therapy to 
diet in adult patients with primary hypercholesterolemia or 
mixed dyslipidemia (Fredrickson types IIa and IIb) to increase 
high-density lipoprotein cholesterol (HDL-C), reduce 
triglycerides (TG), reduce low-density lipoprotein cholesterol 
(LDL-C), reduce total cholesterol (Total-C), and reduce Apo 
lipoprotein B (Apo B).[37,38] 
 
4. Megace ES 
Megace Es (megesterol acetate) was introduced by Par 
Pharmaceutical Companies, Inc. (Spring Valley, NY), who 
licensed the Megace name from Bristol-Myers Squibb (New 
York). Megestrol is a synthetic progestin and has the same 
physiologic effects as natural progesterone. Megestrol also has 
direct cytotoxic effects on breast cancer cells in tissue culture 
and suppresses luteinizing hormone release from the pituitary. 
It is mainly used to improve weight gain and appetite in 
patients undergoing chemotherapy or suffering from an HIV 
infection. The Nanosized drug can be formulated in less 
volume, so the single dose the patient has to take (daily dose 
625 mg of Megestrol in 5 ml of fluid) is reduced by the factor 
four compared to the oral solution available. This reduced 
volume and the improved bioavailability lead to a better patient 
compliance due to the possibility of flexible dosing in order to 
provide effective appetite stimulation and weight gain.[2] 
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Trade   
name 
Drug Indication Applied technology Company Status 
Rapamune Rapamycin Immunosuppressive Nanocrystals élan Wyeth Marketed 
Emend Aprepitant Anti emetic Nanocrystal élan Merck Marketed 
Tricor Fenofibrate Hypercholesterolemia Nanocrystal élan Abbott Marketed 
Megace ES Megestrol Anti anorexic Nanocrystal élan Par Pharmaceutical Companies Marketed 
Triglide Fenofibrate Hypercholesterolemia IDDP Skyepharma Sciele Pharma Inc. Marketed 
Semapimod Guanylhydrazone TNF-α inhibitor Own Cytokine Pharmasciences Phase II 
Paxceed® Paclitaxel Anti inflammatory Unknown Angiotech Phase III 
Theralux® Thymectacin Anti cancer Nanocrystal Élan Celmed Phase II 
Nucryst® Silver Anti bacterial Own Nucryst Pharmaceuticals Phase II 
 
CONCLUSION 
Drug Nanocrystals are considered as the most important 
formulation approaches for poorly water soluble drugs. This 
technology can be applied to any poorly water soluble drugs to 
overcome the solubility and bioavailability problems .The 
decrease in the particle size in the Nano range. Solubility 
enhancement alone is not the only important factor; rather it 
becomes even more important when a drug has a narrow 
therapeutic window where it can be absorbed. In these cases 
the increased solubility and dissolution velocity lead to an 
acceptable bioavailability This technology enables 
formulations to be developed without the need of problematic 
surfactants (e.g. Cremophor EL) which may cause enhanced 
side effects or adverse reactions Nanocrystals also allow for a 
fast action onset, as the drug is absorbed quickly due to the fast 
dissolution of the nanoparticles. This is an advantage, 
especially for drugs which need to work fast (e.g., naproxen for 
headache relief). By modifying the nanocrystals surface it is 
possible to achieve a prolonged or a targeted release. Drug 
nanocrystals is that it can provide smaller dose administration 
to achieve moderate blood level and thus reduce the side effect 
from given larger dosage .It can be applied to various 
administration routes such as oral, parenteral, ocular, 
pulmonary and dermal delivery. The liquid Nanosuspensions 
can be employed as a liquid dosage form or transformed into 
solid dry powder for further production of tablets, capsules, or 
pellets dosage forms. Several techniques can be used to solidify 
the Nanosuspension including the preparation as the 
granulation fluid for tablet production, the layering dispersion 
in fluidized bed process, the use of solid/liquid PEG, spray 
drying and lyophilization. By application of these technology 
produce final dosage forms with higher drug loading capacity, 
better redispersibility at their site of action, as well as an 
improved drug targeting. 
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